首页> 外文期刊>Cell death & disease. >Long non-coding RNA ZNFX1-AS1 promotes the tumor progression and metastasis of colorectal cancer by acting as a competing endogenous RNA of miR-144 to regulate EZH2 expression
【24h】

Long non-coding RNA ZNFX1-AS1 promotes the tumor progression and metastasis of colorectal cancer by acting as a competing endogenous RNA of miR-144 to regulate EZH2 expression

机译:长的非编码RNA ZNFX1-AS1通过充当miR-144竞争性内源RNA来调节EZH2表达,从而促进大肠癌的肿瘤进展和转移

获取原文
           

摘要

Mounting evidences indicated that long non-coding RNA is dysregulated and involved in the pathology of tumors. However, the role of lncRNAs in colorectal cancer (CRC) progression is not fully determined. Differentially expressed lncRNA profile in CRC was conducted by lncRNA microarray in 15 pairs of CRC tissues and adjacent normal tissues, and validated by real-time PCR analysis in another 106 pairs of tissues. The biological effect of lncRNA ZNFX1-AS1 was evaluated by in vitro and in vivo assays. The regulation between lncRNA ZNFX1-AS1 and miR-144 was evaluated by a series of experiments. We found that lncRNA ZNFX1-AS1 expression was significantly upregulated in CRC tissues and cell lines, and the expression of lncRNA ZNFX1-AS1 was associated with aggressive tumor phenotype and poor prognosis in CRC. Functionally, knockdown of lncRNA ZNFX1-AS1 inhibited cell proliferation, invasion, in vitro and tumorigenesis and metastasis in vivo. Further investigation demonstrated that lncRNA ZNFX1-AS1 functioned as a competing endogenous RNA (ceRNA) for miR-144, thereby leading to the depression of its endogenous target gene Polycomb group protein enhancer of zeste homolog 2 (EZH2). We found that lncRNA ZNFX1-AS1 is significantly upregulated in CRC, and the newly identified lncRNA ZNFX1-AS1-miR-144-EZH2 axis is involved in the regulation of CRC progression, which might be used as potential therapeutic targets for CRC patients.
机译:越来越多的证据表明,较长的非编码RNA失调并参与了肿瘤的病理学研究。但是,lncRNA在大肠癌(CRC)进展中的作用尚未完全确定。通过lncRNA基因芯片在15对CRC组织和邻近正常组织中进行差异表达的lncRNA谱分析,并通过实时PCR分析在另外106对组织中进行了验证。通过体外和体内试验评估了lncRNA ZNFX1-AS1的生物学效应。通过一系列实验评估了lncRNA ZNFX1-AS1和miR-144之间的调控。我们发现lncRNA ZNFX1-AS1在CRC组织和细胞系中的表达明显上调,而lncRNA ZNFX1-AS1的表达与CRC的侵袭性肿瘤表型和不良预后有关。在功能上,敲低lncRNA ZNFX1-AS1抑制细胞增殖,侵袭,体外,体内肿瘤发生和转移。进一步的研究表明,lncRNA ZNFX1-AS1充当miR-144的竞争内源RNA(ceRNA),从而导致其内源靶基因zeste同源2的Polycomb组蛋白增强子(EZH2)受到抑制。我们发现,lncRNA ZNFX1-AS1在CRC中显着上调,而新发现的lncRNA ZNFX1-AS1-miR-144-EZH2轴参与了CRC进展的调节,这可能被用作CRC患者的潜在治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号